SynthesisFrontiers in medicine2022
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.
Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Estrone-α-2-Deoxy-Glucoside as a Targeted Therapy for Triple-Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity.Chemical biology & drug design · 2026Article
- Neuroendocrine Tumor Metastases to the Breast Mimic Breast Primary Carcinoma: Mammography and Multimodality US Assessment in Challenging Differential Diagnosis.Diagnostics (Basel, Switzerland) · 2025Article
- Interpretable Machine Learning Algorithms Identify Inetetamab-Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer.Journal of clinical laboratory analysis · 2024Article
- Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.BMC cancer · 2024Article
- Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals.Diagnostics (Basel, Switzerland) · 2024Review
- The Correlation of Body Mass Index with Risk of Recurrence in Post-Menopausal Women with Breast Cancer Undergoing Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.Journal of clinical medicine · 2024Article
- Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer.Medicina (Kaunas, Lithuania) · 2024Review
- [Nuclear medicine and molecular imaging · 2024Article
- Advances in Breast PET Instrumentation.PET clinics · 2024Review
- The Role of Molecular Imaging in Personalized Medicine.Journal of personalized medicine · 2023Review
- Review
- GRPR-targeting radiotheranostics for breast cancer management.Frontiers in medicine · 2023Review
- Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.